Evidence map›Paper›PMID 39174929›Full record

ArticleBMC women's health2024

"Killing two birds with one stone" - a qualitative study on women's perspectives on the dual prevention pill in Johannesburg, South Africa.

Siyanda Tenza, Lydia Mampuru, Mpho Moji, Sihle Zulu, Lorna Begg, Irene V Bruce, Krishnaveni Reddy, Barbara A Friedland, Thesla Palanee-Phillips, Sanyukta Mathur

Abstract read
In one paragraph

Article in BMC women's health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Experiences of adolescent girls and young women of oral PrEP uptake in rural KwaZulu-Natal.African journal of primary health care & family medicine · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Siyanda TenzaFaculty of Health Sciences, Wits RHI, University of the Witwatersrand, Johannesburg, South Africa. stenza@wrhi.ac.za.
Lydia MampuruFaculty of Health Sciences, Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Mpho MojiFaculty of Health Sciences, Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Sihle ZuluFaculty of Health Sciences, Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Lorna BeggCenter for Biomedical Research, Population Council, New York, NY, USA.
Irene V BruceCenter for Biomedical Research, Population Council, New York, NY, USA.
Krishnaveni ReddyFaculty of Health Sciences, Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Barbara A FriedlandCenter for Biomedical Research, Population Council, New York, NY, USA.
Thesla Palanee-PhillipsFaculty of Health Sciences, Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Sanyukta MathurSocial and Behavioral Research, Population Council, Washington, DC, USA.

Funding

WCG sub-agreement # 22010-202-440 in support of the Expanding Effective Contraceptive Options (EECO) project; US Agency for International Development (USAID) COOPERATIVE AGREEMENT # AID-OAA-A-13-00088 Children's Investment Fund Foundation (CIFF) R-1903-03681
6 · The paper itself

Abstract

backgroundHIV incidence remains high in South Africa, with ~ 60% of all new HIV infections among adolescent girls and women (Country factsheets HIV and AIDS Estimates, 2022). Oral pre-exposure prophylaxis (PrEP), approved for HIV prevention in South Africa since 2015, is hampered by low uptake and adherence, particularly among adolescent girls and young women (AGYW). Combining oral PrEP with oral contraceptives could increase PrEP uptake, persistence and address unmet needs for contraception. We investigated the acceptability of a dual prevention pill (DPP), combining oral PrEP and a combined oral contraceptive (COC) for HIV and pregnancy prevention among women in Johannesburg, South Africa.

methodsBetween March-July 2021, we conducted 12 focus group discussions (FGDs) with adolescent girls and women (n = 74) aged 16-40 stratified by ages (16-17, 18-24, 25-40), half of whom were COC users. We explored adolescent girls and women's opinions about the DPP concept, existing HIV and pregnancy prevention options, and input on perceived facilitators and barriers to DPP use. FGDs were conducted in English or isiZulu, using a standardized interview guide. FGDs were audio-recorded, transcribed to English and analyzed using ethnographic content analysis.

resultsThe majority viewed the DPP favorably as a multipurpose option preventing unplanned pregnancy and HIV. Most saw it as a convenient "two-in-one" solution, requiring one clinic visit for both PrEP and COCs. AGYW were viewed as the most likely to benefit from the DPP due to the likelihood of multiple partners and unplanned sex, possibly preventing school dropout from unplanned pregnancy or HIV acquisition. The DPP was perceived to be more reliable than condoms, especially when condom negotiation is limited. Benefits were also seen by participants in rape cases, protecting against pregnancy and HIV. DPP use barriers included side effect concerns, unsupportive partners and judgmental healthcare providers. CONCLUSIONS/SIGNIFICANCE: The DPP was perceived as acceptable for HIV and pregnancy prevention to AGYW in Johannesburg and its dual indications helpful in supporting improved PrEP uptake and persistence. DPP implementation programs need to consider solutions to potential barriers, like education on DPP benefits, coupled with reliable side effect support and healthcare provider sensitization as part of routine sexual health services to encourage uptake and adherence.

Indexed as

Focus GroupsHIV InfectionsPre-Exposure ProphylaxisQualitative ResearchAdolescentAdultContraceptives, Oral, CombinedFemaleHumansPregnancySouth AfricaYoung AdultContraceptives, Oral, CombinedEnd-usersHIV preventionMulti-purpose prevention technology (MPT)Pregnancy preventionQualitative researchSouth Africa

Identifiers

PMID39174929
PMCPMC11342472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.